Trial Outcomes & Findings for Alpha MSH in Ocular Disease (NCT NCT03451578)

Last Updated: 2022-12-22

Results Overview

Recruitment status

COMPLETED

Study phase

Target enrollment

54 participants

Primary outcome timeframe

2 hours

Results posted on

2022-12-22

Participant milestones
Measure	Advanced Dry Macular Degeneration Alpha MSH assay: Assay to detect levels of alpha MSH in intraocular fluid.
Overall Study STARTED	54
Overall Study COMPLETED	54
Overall Study NOT COMPLETED	0

Withdrawal data not reported

Alpha MSH in Ocular Disease

Baseline characteristics by cohort
Measure	Advanced Dry Macular Degeneration n=54 Participants Alpha MSH assay: Assay to detect levels of alpha MSH in intraocular fluid.
Age, Continuous	67.9 years STANDARD_DEVIATION 10.9 • n=5 Participants
Sex: Female, Male Female	34 Participants n=5 Participants
Sex: Female, Male Male	20 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	52 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	2 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	2 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	5 Participants n=5 Participants
Race (NIH/OMB) White	45 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	2 Participants n=5 Participants
Region of Enrollment United States	54 Participants n=5 Participants

Timeframe: 2 hours

Population: Unable to obtain alpha MSH levels.

Outcome data not reported

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

Duke Eye Center

Phone: 919-681-3937